Sermorelin is one of the older prescription peptides still in active clinical use. It is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) — the hypothalamic signal that tells the anterior pituitary to release growth hormone. Unlike recombinant human growth hormone, sermorelin does not replace the hormone directly. It nudges the patient's own pituitary to do the work, on the patient's own pulsatile schedule.
That mechanism matters when you talk about dosing. Sermorelin is not a substitution drug. It is a signal modifier. The protocol is built around amplifying the patient's existing physiology, not overriding it — and that shapes everything about how clinicians select doses, time injections, and structure cycles.
What sermorelin actually does
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary and stimulates the release of growth hormone (GH).1 The downstream effect that gets measured on labs is not GH directly — GH is pulsatile and short-lived in serum — but insulin-like growth factor 1 (IGF-1), which the liver produces in response to GH and which has a much longer half-life. IGF-1 is the practical biomarker for whether a sermorelin protocol is producing the intended endocrine response.
A working protocol typically moves IGF-1 from baseline into the upper-normal range for the patient's age and sex. The clinician is not chasing a supraphysiologic level — overshoot is the failure mode, not the goal — and the dose is calibrated to land in a specific window, not to maximize a number.
Starting doses: weight-based, conservative
Most adult sermorelin protocols start between 100 and 300 mcg, injected subcutaneously once nightly. The clinician chooses a starting dose based on several factors:
- Body weight. Heavier patients sometimes start at the higher end of the range, but the relationship is not linear. A 250-pound patient does not require 2.5 times the dose of a 100-pound patient.
- Age. Older adults — particularly those over 50 — typically have a more responsive somatotroph axis to GHRH stimulation than they do to other secretagogues, but they also tolerate dose escalation more slowly. Conservative starts are routine.
- Prior peptide exposure. Patients who have previously run sermorelin or related GHRH analogs at known doses can sometimes start closer to their prior maintenance dose; first-time users do not.
- Indication. Recovery and sleep-quality goals tend to respond at lower doses. Patients with documented adult growth hormone deficiency may require higher doses under specialist supervision.
Frequency is typically five to six nights per week, with one or two skip nights to reduce receptor downregulation. Daily dosing is used in some protocols but is not the default.
Why evening, and why an empty stomach
The timing rule is the most consistent piece of sermorelin protocol advice in the clinical literature, and it is grounded in basic endocrinology. Endogenous GH release is sharply pulsatile, with the largest pulses occurring during slow-wave sleep — typically within the first ninety minutes after sleep onset.2 Sermorelin given in the evening, thirty to sixty minutes before bed, layers a pharmacologic GHRH signal onto the patient's natural nocturnal pulse rather than competing with daytime negative feedback.
The empty-stomach rule is about insulin and somatostatin. A meal — particularly one with carbohydrate and protein — raises insulin and triggers somatostatin release. Somatostatin is the inhibitory signal that the hypothalamus uses to suppress GH; high circulating somatostatin blunts the pituitary response to GHRH. Patients are asked to leave a two-hour gap between their last meal and the injection so that the somatostatin tone is low when the sermorelin signal arrives.
Patients who inject after a heavy late dinner often report the same set of complaints: groggier mornings, less subjective improvement in recovery, smaller IGF-1 movement on follow-up labs. The clinical team's first adjustment is rarely a dose increase — it is a timing correction.
Cycle length: three to six months, then a planned break
Continuous sermorelin dosing without breaks is uncommon in supervised protocols. The standard pattern is three to six months on, followed by a four-to-eight-week break, then re-evaluation. The break serves two purposes:
- Receptor sensitivity. GHRH receptor downregulation has been documented in animal models and is a plausible mechanism behind the diminishing returns some patients report after extended uninterrupted dosing. A planned break gives the receptor population time to recover responsiveness.
- Clinical re-assessment. A break is also a feedback signal. If the patient's sleep, recovery, and energy hold steady through the off-cycle, the protocol may not need to continue at the prior intensity. If they degrade, the prior dose was contributing — useful information for the next cycle.
Some patients, particularly those with documented adult GH deficiency under specialist care, run continuous protocols. That decision sits with the prescribing clinician and is not the default for general wellness or recovery indications.
Signals that drive dose adjustment
Dose changes on sermorelin are driven by a combination of subjective patient report and objective lab data. The clinical team typically reviews the following at each check-in:
- Sleep architecture and morning energy. Sermorelin's most consistently reported subjective effect is deeper, more restorative sleep within the first few weeks. A patient who reports no sleep change after four to six weeks at a moderate starting dose is either undermedicated, mistimed (see the empty-stomach issue above), or not a strong responder. Worsening sleep — fragmented nights, vivid dreaming that interferes with rest — is a reason to cut the dose, not push it.
- Recovery and training response. Patients on a recovery-oriented protocol often notice it in the gym before they notice it in any other domain: sessions feel less depleting, soreness resolves faster. This is not a dose-escalation trigger by itself, but its absence over an eight-to-twelve-week window is.
- IGF-1 trajectory. A baseline IGF-1 is drawn before the first injection, and follow-up labs are typically pulled at six to eight weeks and again at the end of the cycle. The clinician is looking for movement into the upper-normal range for age. A flat IGF-1 at a reasonable dose is a reason to reconsider — either the dose, the timing, or whether the patient is a candidate at all.
- Injection-site tolerance. Sermorelin is generally well tolerated, but local reactions — redness, mild swelling, transient itching — are common in the first few weeks. Persistent or worsening site reactions across the cycle are a reason to rotate sites more aggressively or to evaluate the compounded preparation itself.
A common trap for self-directed users is escalating dose in pursuit of a stronger subjective signal. The clinical reality is that sermorelin's response curve is not linear at the high end. Doses above the patient's individual sweet spot tend to produce more side effects without proportionally more benefit, and they push IGF-1 toward the supraphysiologic range that nobody is targeting.
Where TelePeptide fits
TelePeptide's clinicians prescribe sermorelin individually, with starting doses, cycle length, and adjustment cadence determined by intake data and ongoing labs. Compounded preparations are made by licensed 503A pharmacies in response to a specific patient prescription. Compounded medications are not FDA-approved.
Patients on sermorelin protocols are scheduled for IGF-1 lab draws at predictable intervals — typically baseline, six-to-eight weeks, and end of cycle — with check-ins between draws to track sleep, recovery, and injection-site tolerance. Dose adjustments are made by the clinician, not the patient, and the protocol is paused or revised when the signal-to-side-effect ratio shifts.
These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. Sermorelin is a prescription peptide; eligibility is determined individually by a licensed clinician.
Footnotes
FAQ
Common questions
What is a typical sermorelin starting dose?
Most adult protocols begin between 100 and 300 mcg subcutaneously, dosed once nightly five to six nights per week. The clinician selects the starting dose based on body weight, age, prior peptide exposure, and the indication being addressed. Higher starting doses are not better — they raise the chance of injection-site reactions and tolerability problems without improving the downstream IGF-1 response in most patients.
Why is sermorelin dosed in the evening?
Endogenous growth hormone is released in pulses during slow-wave sleep, with the largest pulse typically occurring within the first ninety minutes after sleep onset. Evening dosing aligns the sermorelin signal with that natural pulse rather than competing with it. Patients are usually asked to inject thirty to sixty minutes before bedtime on an empty stomach.
How long is a typical sermorelin cycle?
Three to six months on, followed by a planned break of four to eight weeks, is a common pattern. The break is not a fashion preference — it gives the pituitary axis a window without exogenous secretagogue input and lets the clinician reassess whether continued dosing is producing the intended effect. Some patients run continuous protocols under closer monitoring; others cycle more aggressively.
What signals tell a clinician to adjust the dose?
Sleep quality, recovery between training sessions, IGF-1 movement on lab work, and tolerability — particularly injection-site reactions and morning grogginess. A flat IGF-1 after eight to twelve weeks at a moderate dose is a reason to consider escalation or to re-evaluate the protocol entirely. A rising IGF-1 with worsening sleep is a reason to pull the dose back, not push it higher.
Can sermorelin be self-titrated by the patient?
No. Sermorelin is a prescription peptide, and the dose, frequency, and cycle structure are clinician-determined. Self-titration without lab monitoring removes the feedback signal — IGF-1 — that the protocol depends on. Patients can and should report subjective changes (sleep, recovery, side effects) so the clinician can adjust accordingly.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.